Marinomed Biotech AG

MARI

ATMARINOMED6

Pharmaceuticals

Market Closed - Wiener Boerse Other stock markets 11:35:08 2024-05-28 EDT			5-day change	1st Jan Change
14.35 ^EUR	-1.71%		-12.50%	-50.86%

04-16	Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024
04-16	Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Marinomed Biotech AG Provides Earnings Guidance for the Year 2021

November 22, 2021 at 01:00 am

Marinomed Biotech AG provided earnings guidance for the year 2021. For the year, the company expects an operating loss for 2021 in line with its business plan and aims to reach profitability in the medium term.

Latest news about Marinomed Biotech AG

Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024	04-16
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Marinomed Biotech Considers Partnerships, Potential Transfer of Carragelose Portfolio	12-18	MT
Marinomed Biotech Signs Deal With DKSH to Commercialize Carragelose in Four Countries	12-14	MT
Transcript : Marinomed Biotech AG, Nine Months 2023 Earnings Call, Nov 21, 2023	11-21
Marinomed Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-21	CI
Transcript : Marinomed Biotech AG, H1 2023 Earnings Call, Aug 17, 2023	23-08-17
Marinomed Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Marinomed Biotech Enters Technical Cooperation with Chinese Pharmaceutical Group	23-08-09	MT
Austria’s Marinomed Biotech Secures Mexican Market Authorization for Nasal Spray	23-07-27	MT
Marinomed Biotech AG Announces Changes to Its Board	23-06-21	CI
Transcript : Marinomed Biotech AG, Q1 2023 Earnings Call, May 23, 2023	23-05-23
Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Transcript : Marinomed Biotech AG, 2022 Earnings Call, Apr 19, 2023	23-04-19
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Austria's Marinomed Biotech Secures US Patent for Solubilization Technology	22-12-27	MT
Marinomed Biotech AG Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-21	CI
Marinomed Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022	22-08-25	CI
Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022	22-07-07	CI
Marinomed Biotech AG Announces Management Appointments	22-06-15	CI
Transcript : Marinomed Biotech AG, Q1 2022 Earnings Call, May 23, 2022	22-05-23
Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022	22-05-23	CI
Marinomed Biotech AG Enters into License Agreement with Proc & Gamble on Carragelose Products	22-05-19	CI
Transcript : Marinomed Biotech AG, 2021 Earnings Call, Apr 13, 2022	22-04-13

Chart Marinomed Biotech AG

Duration

Period

More charts

Company Profile

Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.

Sector

Pharmaceuticals

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Marinomed Biotech AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.6 EUR

Average target price

63 EUR

Spread / Average Target

+331.51%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MARINOMED BIOTECH AG	-50.86%	24.42M
CSL LIMITED	-1.64%	90.28B
SAMSUNG BIOLOGICS CO.,LTD.	-1.97%	39.5B
BIOGEN INC.	-15.95%	31.71B
UCB	+61.28%	26.41B
BIOMARIN PHARMACEUTICAL INC.	-22.86%	14.34B
INCYTE CORPORATION	-9.21%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.77%	11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.97%	10.95B
SWEDISH ORPHAN BIOVITRUM AB	+3.30%	8.85B

Biopharmaceuticals